Lotte Biologics, a dynamic subsidiary of South Korea’s Lotte Group, is a rising force in the biopharmaceutical contract manufacturing sector. Established in 2022, it has quickly positioned itself as a global Contract Development and Manufacturing Organization (CDMO) focused on high-quality biologics production.

Lotte Biologics provides end-to-end services, specialising in the development and manufacture of biologic drug substances. The company operates a state-of-the-art facility, previously owned by Bristol Myers Squibb, located in Syracuse, New York, which offers drug substance manufacturing with a substantial production capacity of 35,000L across its bioreactors. This site is fully GMP-compliant, with capabilities for both clinical and commercial-scale operations. Lotte Biologics is also expanding rapidly, with plans to establish multiple “mega plants” in South Korea by 2030, further enhancing its capacity to meet the growing global demand for biologics.

Key products and services include:

• Biologics contract manufacturing services (clinical and commercial scale)
• Drug substance production with bioreactor capacities up to 35,000L
• Full GMP and regulatory compliance across multiple global markets, including FDA, EMA, and PMDA approvals
• Integrated manufacturing solutions for biologics, from process development to final production
• Facility expansion plans targeting a combined 360,000L bioreactor capacity by 2030.